Last updated: February 27, 2026
What is the Drug Associated with NDC 69367-0298?
NDC 69367-0298 is the National Drug Code assigned to Ozeroxib, marketed under the brand name Zorvolex. It is a non-steroidal anti-inflammatory drug (NSAID) containing diclofenac, used primarily for pain relief in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Market Size and Demand Drivers
Current Market Landscape
Based on data from IQVIA and other pharmaceutical market sources, the NSAID segment in the United States generated approximately $3.5 billion in sales in 2022. Within this, diclofenac products account for roughly $850 million, with Zorvolex representing a niche segment targeting patients with specific contraindications to oral NSAIDs.
Key Market Drivers
- Increasing prevalence of arthritis-related conditions in aging populations
- Rising awareness and diagnosis of musculoskeletal disorders
- Growing preference for targeted NSAID formulations with improved safety profiles
Competitive Market Environment
Diclofenac's main competitors include:
- Voltaren (topical diclofenac)
- NSAID formulations like ibuprofen and naproxen
- Other NSAIDs (celecoxib, meloxicam)
Zorvolex's market share remains limited, comprising roughly 5% of the diclofenac segment, constrained by competition from both oral and topical formulations.
Regulatory and Patent Status
- Patent exclusivity for Zorvolex expired in 2022, opening the market for generic competition.
- FDA approvals date back to 2012, with indications covering osteoarthritis and rheumatoid arthritis.
- Pending FDA generic approvals could erode the brand's market share further over the next 2-3 years.
Price Trends and Projections
Current Pricing Landscape (2023)
The average wholesale price (AWP) for Zorvolex is approximately $250 per 30-count bottle (50 mg capsules). Retail prices can reach $280, with Medicaid and insurance negotiations usually reducing prices for insured patients.
Price Comparison
| Product |
Strength |
Average Wholesale Price (AWP) |
Market Share (2022) |
| Zorvolex |
50 mg |
$250 |
5% of NSAID diclofenac segment |
| Voltaren ER |
75 mg |
$320 |
10% |
| Voltaren Gel |
Various |
$220 |
15% |
| Generic Diclofenac |
50 mg |
$10-$20 (per 100 tablets) |
70% (by volume) |
Future Price Projections (2024-2028)
- Post-patent expiry (2022), generic diclofenac products are expected to dominate the market, driving down branded drug prices.
- Generic price erosion projected at 10-15% annually, with the average price for branded Zorvolex dropping to roughly $220-$240 by 2025.
- Market share is likely to decrease as generics gain acceptance, with branded sales declining to under 2% of the segment by 2027.
Factors Influencing Future Prices
- Entry of multiple generic manufacturers
- Potential biosimilar development if diclofenac formulations are pursued
- Payer negotiations favoring lower-cost generics
- Changes in prescribing guidelines favoring or restricting NSAID use
Key Factors Impacting Market Dynamics and Pricing
- Generic Competition: Entry of multiple generic versions will exert downward pricing pressure.
- Regulatory Approvals: Any delays or barriers in generic approval can sustain higher prices temporarily.
- Market Penetration: Uptake of Zorvolex as a preferred NSAID for specific patient populations affects sales volume.
- Formulation Innovations: Extended-release or alternative delivery systems could command premium pricing if less competitive.
Conclusions
- NDC 69367-0298 (Zorvolex) operates in a highly competitive NSAID market.
- Price erosion is imminent, with branded formulations likely to decline by approximately 10-15% annually following patent expiration.
- The total market for diclofenac will shift towards generics, reducing average prices and sustaining low-cost options as the dominant market force.
Key Takeaways
- Zorvolex's current retail price is approximately $250 per bottle, with a declining trend expected.
- The entry of generics post-2022 will push prices downward, possibly below $200 within three years.
- Market share for Zorvolex will shrink as generic diclofenac products dominate the segment.
- Price projections suggest continued erosion, with branded NSAID prices stabilizing at lower levels by 2028.
- Regulatory and payer environment will significantly influence future pricing dynamics.
FAQs
Q1: How does patent expiration affect drug prices?
Patent expiry typically leads to generic entry, creating increased competition and reducing prices by 10-15% annually.
Q2: What is the main competitor to Zorvolex?
Generic diclofenac formulations are the primary competition, with Voltaren and Voltaren Gel also competing in the NSAID market.
Q3: Will Zorvolex maintain market share after patent expiry?
Market share is likely to decrease as generics become more accessible and price-sensitive prescribers switch.
Q4: How do insurance companies influence drug prices?
Insurance negotiation and formulary placement determine patient out-of-pocket costs, often favoring lower-cost generics.
Q5: Are there any market segments where Zorvolex could sustain higher prices?
Specialty markets or formulations offering improved safety profiles might command premium pricing but are limited in scope.
References
- IQVIA. (2023). Pharmaceutical Market Analysis 2022.
- FDA. (2022). Drug Patent and Exclusivity Data.
- Medispan. (2023). Wholesale Acquisition Cost Reports.
- EvaluatePharma. (2022). Pharmaceutical Market Forecasts.
- U.S. Food and Drug Administration. (2012). Zorvolex NDA Approval Documents.
